Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHC 014748M

Next Previous
Drug Profile

SHC 014748M

Alternative Names: SH748M; SHC014748M

Latest Information Update: 28 Aug 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nanjing Sanhome Pharmaceutical
  • Class Antineoplastics; Heterocyclic compounds; Pyrimidines
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Follicular lymphoma; Marginal zone B-cell lymphoma
  • No development reported Haematological malignancies

Most Recent Events

  • 28 Aug 2021 No recent reports of development identified for phase-I development in Haematological-malignancies(Refractory metastatic disease, Second-line therapy or greater) in China (PO, Capsule)
  • 14 Jul 2020 Nanjing Sanhome Pharmaceutical plans a phase II trial for Peripheral T-cell lymphoma (Second-line therapy or greater) in August 2020 (NCT04470141)
  • 16 Jun 2020 Nanjing Sanhome Pharmaceutical plans a phase II trial in Follicular lymphoma (Second-line therapy or greater) or Marginal zone B-cell lymphoma (Second-line therapy or greater) in China (PO) in June 2020 (NCT04431089)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top